# Cumberland Pharmaceuticals

Cumberland Pharmaceuticals is an Asset Manager based in Nashville, United States.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** Nashville, United States
- **Region:** North America
- **Address:** Nashville, TN, United States
- **Founded:** 1999
- **Assets under management:** Undisclosed
- **Website:** cumberlandpharma.com

## Regulatory record

- **Reports private funds:** No

## About

Cumberland Pharmaceuticals was founded in Nashville, Tennessee in 1999 by A.J. Kazimi, who has continuously served as CEO. The company operates as a publicly traded specialty pharmaceutical firm rather than a family office or traditional asset manager, focusing on the acquisition, development, and commercialization of prescription products for the hospital acute-care and gastroenterology markets. As of its most recent filings, the company has grown to approximately 91 professional employees. The company's commercial strategy centers on targeting niche medical conditions where large pharmaceutical companies lack market focus. Its portfolio spans acute care, gastroenterology, and oncology. Key named products generating revenue include Ethyol, an FDA-approved cytoprotective agent for reducing chemotherapy side effects; Kristalose, a prescription laxative; Sancuso, a transdermal patch for chemotherapy-induced nausea; and Caldolor, an intravenous formulation of ibuprofen for pain and fever management. Cumberland deploys an internal hospital-sales force to market these products directly to physicians and pharmacists across the United States. Cumberland has augmented organic sales through strategic acquisitions. In recent years, it expanded its oncology portfolio by acquiring Sancuso and Methotrexate from a competitor. The company also supports an emerging pipeline via its Cumberland Emerging Technologies division, which partners with academic medical centers to advance early-stage drug candidates. A notable operational event occurred in February 2024 when it launched a new initiative with the FDA to resolve a clinical hold on a future-phase program for Ifetroban, a drug for a rare form of heart disease (per the firm, February 2024). Cumberland's structural differentiator is its position as a publicly traded, hospital-focused specialty pharma aggregator rather than a drug-discovery startup or a large generic manufacturer. The firm targets low-competition, established molecules that still require branded marketing attention, avoiding the binary risk of single-compound biotechs while maintaining higher margins than pure-play generic companies. Kazimi's decades-long tenure as CEO provides continuity across an acquisitive strategy that has rewarded shareholders with a stable, if non-explosive, revenue base.

## Sectors

- Pharmaceuticals

## People

- A. J. Kazimi — Chief Executive Officer

## Questions

### Is Cumberland Pharmaceuticals an investment firm or an operating company?

Cumberland is an operating company listed on NASDAQ (ticker: CPIX). It is not a fund, family office, or advisory firm. It operates directly in the pharmaceutical sector, marketing and acquiring branded prescription products primarily for hospital and acute-care use.

### Who controls the strategic direction at Cumberland?

A.J. Kazimi founded the company in 1999 and remains Chairman and CEO, controlling the strategic direction. All major product acquisitions and FDA-facing pipeline decisions ultimately route through the executive team under Kazimi's leadership.

### What categories of therapeutic drugs does Cumberland focus on?

Cumberland specifically targets acute hospital care, gastroenterology, and oncology. Key products include Caldolor (an IV form of ibuprofen for pain and fever), Kristalose (a prescription laxative), and Ethyol (to reduce toxicities associated with chemotherapy).

### How does Cumberland Pharmaceuticals source its pipeline?

The firm sources products through direct acquisitions of existing FDA-approved drugs from larger pharmaceutical companies and through its affiliated early-stage program, Cumberland Emerging Technologies. The latter partners with academic medical centers to develop new therapeutic candidates.

## Related profiles

- [Rein Therapeutics](https://altss.com/profile/rein-therapeutics-inc)
- [Virtus Global Multi-Sector Income Fund](https://altss.com/profile/virtus-global-multi-sector-income-fund)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/cumberland-pharmaceuticals-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology